Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation.

Trial Profile

Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Acronyms TRIPLETE RESET
  • Most Recent Events

    • 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Dec 2012 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 05 Nov 2012 Planned initiation date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top